References
1. Downing JR, Shannon KM. Acute leukemia: a pediatric perspective.Cancer Cell. 2002;2(6):437-445.
2. Harvey RC, Tasian SK. Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia.Blood Adv. 2020;4(1):218-228.
3. Roberts KG, Reshmi SC, Harvey RC, et al. Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children’s Oncology Group. Blood. 2018;132(8):815-824.
4. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med.2014;371(11):1005-1015.
5. McClain KL, Bigenwald C, Collin M, et al. Histiocytic disorders.Nat Rev Dis Primers. 2021;7(1):73.
6. Castro EC, Blazquez C, Boyd J, et al. Clinicopathologic features of histiocytic lesions following ALL, with a review of the literature.Pediatr Dev Pathol. 2010;13(3):225-237.
7. Fenu EM, Margolskee E, Pillai V. Transdifferentiation of B-lymphoblastic leukemia to histiocytic sarcoma after immunotherapy.Am J Hematol. 2023;98(8):E216-E218.
8. Kato M, Seki M, Yoshida K, et al. Genomic analysis of clonal origin of Langerhans cell histiocytosis following acute lymphoblastic leukaemia. Br J Haematol. 2016;175(1):169-172.
9. Pawinska-Wa Sikowska K, Cwiklinska M, Wyrobek E, et al. Disseminated Juvenile Xanthogranuloma and Hemophagocytic Lymphohistiocytosis Developed During Treatment of Acute Lymphoblastic Leukemia: Case Report.Front Oncol. 2020;10:921.
10. Feldman AL, Minniti C, Santi M, Downing JR, Raffeld M, Jaffe ES. Histiocytic sarcoma after acute lymphoblastic leukaemia: a common clonal origin. Lancet Oncol. 2004;5(4):248-250.
11. Newman H, MacFarland SP, Brodeur GM, et al. B-cell acute lymphoblastic leukemia and juvenile xanthogranuloma in a patient with ETV6 thrombocytopenia and leukemia predisposition syndrome: novel clinical presentation and perspective. Haematologica. 2023.
12. Salzer WL, Burke MJ, Devidas M, et al. Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children’s Oncology Group study AALL1131. Cancer. 2018;124(6):1150-1159.
13. Aparicio G, Mollet J, Bartralot R, et al. Eruptive juvenile xanthogranuloma associated with relapsing acute lymphoblastic leukemia.Pediatr Dermatol. 2008;25(4):487-488.
14. Bailey KM, Castle VP, Hummel JM, Piert M, Moyer J, McAllister-Lucas LM. Thalidomide therapy for aggressive histiocytic lesions in the pediatric population. J Pediatr Hematol Oncol.2012;34(6):480-483.
15. Cheon E, Yang S, Han JH, Lee KC, Park JE. Systemic Juvenile Xanthogranuloma Involving the Bone Marrow, Multiple Bones, and the Skin That Developed During Treatment of Acute Lymphoblastic Leukemia in Remission State. Pediatr Dev Pathol. 2018;21(5):489-493.
16. Perez-Becker R, Szczepanowski M, Leuschner I, et al. An aggressive systemic juvenile xanthogranuloma clonally related to a preceding T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer.2011;56(5):859-862.
17. Rotte JJ, de Vaan GA, Koopman RJ. Juvenile xanthogranuloma and acute leukemia: a case report. Med Pediatr Oncol. 1994;23(1):57-59.
18. Morier P, Merot Y, Paccaud D, Beck D, Frenk E. Juvenile chronic granulocytic leukemia, juvenile xanthogranulomas, and neurofibromatosis. Case report and review of the literature. J Am Acad Dermatol.1990;22(5 Pt 2):962-965.
19. Paxton CN, O’Malley DP, Bellizzi AM, et al. Genetic evaluation of juvenile xanthogranuloma: genomic abnormalities are uncommon in solitary lesions, advanced cases may show more complexity. Mod Pathol.2017;30(9):1234-1240.
20. Egan C, Lack J, Skarshaug S, et al. The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy. Mod Pathol. 2021;34(2):336-347.
21. Irving J, Matheson E, Minto L, et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 2014;124(23):3420-3430.
22. Feldman AL, Berthold F, Arceci RJ, et al. Clonal relationship between precursor T-lymphoblastic leukaemia/lymphoma and Langerhans-cell histiocytosis. Lancet Oncol. 2005;6(6):435-437.